blank
blank
es4

Methodology Services for Rare Disease Research

Designing clinical studies for rare diseases comes with unique challenges. Each patient often contributes a rich and complex medical story but the number of patients is small. This leads to data that are diverse, detailed, and sometimes incomplete. To turn this complexity into scientific strength, we provide advanced methodological support for researchers across Europe .

By bringing together specialists in biostatistics, epidemiology, data science, artificial intelligence, and machine learning, we aim to empower clinical research networks and healthcare centres with the best tools to conduct high-quality studies in rare diseases.​

Our goal is to turn complex data into clear answers that benefit patients living with rare diseases.​

How We Work With You

We offer hands-on expertise directly to research teams within ERDERA or with funded projects conducting clinical trials or working with real-world evidence. We also work closely with regulatory specialists to explore qualification pathways for innovative methods, helping them gain recognition and adoption across Europe. Get in touch with us for additional information.

What We Do

Our teams across different institutions in Europe help research groups choose and apply the most suitable study designs and statistical methods for rare disease research.

We support projects using:

  • Clinical trials
  • Real-World Data, including registries and epidemiological studies
  • Mixed data sources, combining clinical and real-world evidence

We use a wide range of cutting-edge methods such as Bayesian and likelihood-based approaches, randomization techniques, and modern comparison tools, to ensure analyses are robust, precise and tailored to small populations.

Why It Matters

Over the past decade, European collaborations have shown that adapted methodologies dramatically improve the value of clinical studies for rare diseases. Building on this strong foundation, our service accelerates:

  • The implementation of proven methods developed specifically for small populations
  • The development of new approaches where gaps and unmet needs remain

This helps ensure that promising innovations reach clinical teams and patients more efficiently.

Relevant Publications and Resources

Pharmacometrics

A Pharmacometrics-Informed Trial Simulation Framework for Optimizing Study Designs for Disease-Modifying Treatments in Rare Neurological Disorders

A new simulation framework leverages pharmacometrics to optimise clinical trial designs for disease-modifying treatments in rare neurological conditions.
orphanet

Reflection on clinical and methodological issues in rare disease clinical trials

Experts provide a comprehensive reflection on the unique clinical and methodological challenges inherent in designing and executing trials for rare diseases.
Epilepsy & Behaviour

Dravet syndrome: Insights into seizure and speech progression from registry data

Analysis of registry data offers critical insights into the progression of seizures and speech development in patients with Dravet syndrome.

The ERDERA Innovation Management Toolbox

Explore connected resources via an interactive interface that visually represents relationships between datasets, samples, and research projects.

FAQ Section

Useful when looking for something specific or attempting to navigate processes.

Contact the Methodoloy Services

Get in touch with our pool of experts.

You might also be interested in

stocksnap-people-2574170_1920

EMA launches consultation on proof-of-concept data in paediatric oncology

This initiative is also highly relevant from a rare diseases perspective, as paediatric cancers are rare conditions where small patient populations make robust non‑clinical proof‑of‑concept data essential for responsible and ethical trial initiation.
kitt_ks-lab-2107514_1920

Towards animal-free testing: virtual control groups gain regulatory acceptance

For rare diseases, where research often relies on limited animal models and small development teams, the regulatory acceptance of virtual control groups could help streamline early non‑clinical studies while maintaining a strong focus on patient safety.
Captura de pantalla 2026-04-08 142004

Advancement of Treatments for Rare Diseases

The two-day event will focus on translating research and policy initiatives into tangible benefits for Rare Disease patients through better prevention, diagnosis, and treatment.
Publicaciones (1)

EU rare disease action plan- European Added Value Assessment

This study investigates possible measures that could be taken at EU level to address these challenges. It finds significant European added value in harmonising coordination and access across the 27 Member States, mainly in terms of improved diagnostic tools and availability of medical treatment, better health outcomes, particularly lower infant mortality, and improved well-being of family members and caregivers.

ERDERA's

search form